|1.||Movement Disorders (Movement Disorder)
|3.||Parkinson Disease (Parkinson's Disease)
|1.||Kawanishi, Chiaki: 7 articles (11/2007 - 01/2003)|
|2.||Nisijima, Koichi: 5 articles (12/2015 - 01/2007)|
|3.||Tanii, Hisashi: 5 articles (01/2012 - 03/2006)|
|4.||Caroff, Stanley N: 5 articles (02/2011 - 11/2002)|
|5.||Kato, Daiji: 5 articles (11/2007 - 03/2005)|
|6.||Kishida, Ikuko: 5 articles (11/2007 - 03/2003)|
|7.||Hirayasu, Yoshio: 5 articles (11/2007 - 03/2005)|
|8.||Duggal, Harpreet S: 4 articles (01/2007 - 01/2004)|
|9.||Matsumura, Takehiko: 4 articles (10/2006 - 03/2003)|
|10.||Bourgeois, James A: 4 articles (02/2006 - 01/2002)|
|1.||Dantrolene (Dantrium)FDA LinkGeneric
03/01/2014 - "On suspicion of neuroleptic malignant syndrome(NMS) onset, dantrolene sodium hydrate was administered, resulting in marked improvement of the symptoms. "
02/01/2010 - "She received infusion of 140 mg dantrolene in total under suspicion of having neuroleptic malignant syndrome, but her symptoms improved slightly. "
05/01/1998 - "Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome."
01/01/2012 - "Under a diagnosis of neuroleptic malignant syndrome, dantrolene was administered. "
09/01/2003 - "Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene."
|2.||Bromocriptine (Parlodel)FDA LinkGeneric
02/01/1986 - "This constellation of symptoms, known as the neuroleptic malignant syndrome (NMS), partially improved when the neuroleptic medication was stopped, but complete resolution of the syndrome did not occur until the patient was treated with bromocriptine. "
04/01/1991 - "Neuroleptic malignant syndrome improved by bromocriptine."
05/01/1990 - "Neuroleptic malignant syndrome improved by bromocriptine."
05/01/2011 - "We present the first case report of neuroleptic malignant syndrome associated with the withdrawal of bromocriptine. "
03/01/1996 - "Bromocriptine (BROMO), which is used for the treatment of neuroleptic malignant syndrome, also decreased NK cell activity. "
|3.||Antipsychotic Agents (Antipsychotics)IBA
04/01/2012 - "However, to clarify whether there is a difference in neuroleptic malignant syndrome-related mortality with the 2 types of antipsychotics, further studies with larger samples are needed."
04/01/2012 - "Propensity score matching was performed to formulate a balanced 1:1 matched study and to compare in-hospital mortality between neuroleptic malignant syndrome patients taking typical antipsychotics and those taking atypical antipsychotics. "
01/01/2007 - "This case series study examines the hypothesis that neuroleptic malignant syndrome (NMS) is a heterogeneous condition including catatonic variants and non-catatonic pathological reactions to antipsychotics. "
08/01/2015 - "Neuroleptic malignant syndrome (NMS) is a life-threatening neurologic emergency associated with the use of mainly typical antipsychotic drugs. "
03/01/2015 - "Neuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse reaction to antipsychotics. "
|4.||Clozapine (Clozaril)FDA LinkGeneric
01/01/2002 - "Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome."
09/01/2014 - "Rechallenging clozapine after neuroleptic malignant syndrome."
01/01/2014 - "Fatal neuroleptic malignant syndrome induced by clozapine in Parkinson's psychosis."
08/01/2012 - "Clozapine-induced neuroleptic malignant syndrome in an adolescent."
04/01/2012 - "Early identification and treatment is critical to lower the mortality of clozapine-associated neuroleptic malignant syndrome."
|5.||Diazepam (Valium)FDA LinkGeneric
10/01/1995 - "He developed neuroleptic malignant syndrome (NMS) which was treated successfully with intravenous diazepam. "
10/01/2013 - "Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report."
06/01/1997 - "Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype?"
11/01/1988 - "Neuroleptic malignant syndrome treated with Diazepam."
09/01/1988 - "A mild form of neuroleptic malignant syndrome (NMS) in a schizophrenic patient who was receiving a depot neuroleptic is described and beneficial response to oral diazepam 50 mg daily is reported."
|6.||Haloperidol (Haldol)FDA LinkGeneric
11/01/2015 - "The high drug sensitivity of DLB was considered the cause of neuroleptic malignant syndrome induced by haloperidol. "
05/01/2014 - "The paper reports on a rare case of fulminant neuroleptic malignant syndrome (NMS) with several risk factors, typical manifestation and rapid death induced by low doses of haloperidol. "
05/01/2014 - "Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: a rare case."
09/01/2013 - "We present that case of an 81-year old woman who was admitted to the Psychiatric Hospitalization Unit (PHU) for a depressive episode with psychotic symptoms who developed a neuroleptic malignant syndrome (NMS) when Haloperidol was introduced. "
01/01/2013 - "Neuroleptic malignant syndrome (NMS) associated with haloperidol was suspected. "
12/01/2012 - "Lithium-induced fatal neuroleptic malignant syndrome in a patient not being concomitantly treated with commonly offending agents."
01/01/2012 - "This case illustrates that lithium toxicity can occur within therapeutic levels, and the neurotoxic effect of lithium can include Neuroleptic Malignant Syndrome. "
01/01/2012 - "Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity."
06/01/2003 - "Acute lithium intoxication and neuroleptic malignant syndrome."
10/01/2000 - "The purpose of this report is to remind clinicians of the risk of the simultaneous occurrence of neuroleptic malignant syndrome (NMS) and lithium intoxication. "
|9.||olanzapine (Zyprexa)FDA Link
10/01/2007 - "We aimed in this study to evaluate the successfully cured case of neuroleptic malignant syndrome induced by olanzapine in postpartum period with the literature view."
01/01/2015 - "Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery."
10/01/2013 - "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment."
01/01/2013 - "Olanzapine induced neuroleptic malignant syndrome."
02/01/2009 - "A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported. "
|10.||Risperidone (Risperdal Consta)FDA LinkGeneric
02/01/2013 - "Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report."
05/01/2009 - "We postulate a possible interaction between risperidone and neuroleptic malignant syndrome and we suggest to use risperidone with caution in both young and middle aged people."
05/01/2009 - "A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman."
07/01/2008 - "A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone."
03/12/2005 - "[Neuroleptic malignant syndrome in users of risperidone]."
12/01/2014 - "A massive asymptomatic creatine kinase elevation (MACKE) has been described during antipsychotic exposure in adult psychotic patients without signs of neuroleptic malignant syndrome (NMS), or other most frequent reasons for high creatine kinase (CK) serum level (intramuscular injections, restraints, intense physical activity, dystonic reactions). "
10/01/1989 - "Patients with neuroleptic malignant syndrome displayed significantly greater psychomotor agitation, received significantly higher doses of neuroleptics at greater rates of dosage increase, and received a greater number of intramuscular injections than controls."
11/01/1998 - "The files of 183 hospitalized children and adolescents (93 boys, 90 girls) with severe psychiatric disorders were reviewed for serum creatine kinase activity on admission, psychomotor agitation, Clinical Global Impression Score, need for intramuscular injection, number of neuroleptic medications and presence of neuroleptic malignant syndrome. "
|3.||Induced Hyperthermia (Thermotherapy)
11/01/1995 - "Neuroleptic Malignant Syndrome (NMS) is a rare but potentially lethal form of drug-induced hyperthermia. "
04/01/2004 - "We describe four cases with advanced stage Huntington's disease who within a period of one year developed drug-induced hyperthermia, either the neuroleptic malignant syndrome, or the serotonin syndrome. "
01/01/2002 - "The neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of neuroleptic drug-induced hyperthermia, altered level of consciousness, extrapyramidal effects, autonomic instability and muscle rigidity. "
07/01/1998 - "Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of drug-induced hyperthermia characterised by mental status changes, muscle rigidity, hyperthermia and autonomic dysfunction. "
10/01/1997 - "This article reviews the pathophysiology, presentation, and treatment of several drug-induced hyperthermia syndromes: malignant hyperthermia, neuroleptic malignant syndrome, sympathomimetic poisoning, and anticholinergic toxicity. "
03/13/1995 - "Changes are that D2 receptors in the human LH could be responsible for the neuroleptic malignant syndrome (NMS), and that sulpiride injections in the rat LH could be used as a model for the study of the pathogenesis of this syndrome."
10/01/2008 - "Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report."
|5.||Drug Therapy (Chemotherapy)
11/01/2001 - "Neuroleptic malignant syndrome can be a serious neurologic complication of drug therapy during pregnancy. "
06/01/1995 - "The neuroleptic malignant syndrome (NMS) is a potentially fatal complication of antipsychotic pharmacotherapy. "
11/01/1988 - "Neuroleptic malignant syndrome is an uncommon, occasionally lethal reaction to drug therapy. "
01/01/1986 - "The neuroleptic malignant syndrome (NMS) is an under-recognized yet sometimes fatal complication of antipsychotic drug therapy. "
06/01/1988 - "Neuroleptic malignant syndrome is a complication of neuroleptic drug therapy; skeletal muscle hypertonicity helps distinguish this entity from heat stroke. "